Top Performing Stocks To Own For 2014

LONDON -- Weir� (LSE: WEIR  ) released its interim management statement for the four months between Dec. 29, 2012, to April 30, 2013, this morning, with its share price falling 1.3% in early trade following a mixed reaction by the market.

This followed the announcement of a lower opening order book in the first quarter, down 14% on a reported basis against the same period last year, with the oil and gas division particular underperforming and contributing to lower revenues. Management also stated that "operating profits were down on the prior year period, with margins also affected by one-off costs in relation to the continued restructuring of the pressure pumping operations".

Like-for-like input in the first quarter saw a 14% decline against Q1 2012 but an increase of 14% against Q4 2012, with growth seen in minerals and oil and gas.�Original equipment input was 23% lower than the comparative quarter last year, which saw a number of large project orders.

Top Performing Stocks To Own For 2014: (OFSS.NS)

Oracle Financial Services Software Limited, together with its subsidiaries, provides information technology (IT) solutions and knowledge processing services to the financial services industry worldwide. The company offers Oracle FLEXCUBE, a banking product suite for consumer, corporate, investment, mobile and Internet banking, consumer lending, asset management, and investor servicing, including payments. Its products comprise Oracle FLEXCUBE Enterprise Limits and Collateral Management, which enables centralized collateral management, limits definition, tracking, and exposure measurement; Oracle FLEXCUBE Private Banking solution that offers a wealth management portal, a customer interaction tool, and portfolio management capabilities for private banking; and Oracle FLEXCUBE Investor Servicing, a process enabled transfer agency and investor servicing solution. The company also offers Oracle Financial Services Analytical Applications for enterprise risk, performance manageme nt, regulatory compliance, and customer insight; consulting services in the areas of business transformation, risk and compliance, program management, IT architecture, IT governance, and process improvement; and application services for banking, securities, and insurance. In addition, it provides technology services comprising conceptualization, design, evaluation, implementation, and management of IT infrastructure for financial institutions; business process outsourcing services ranging from back office work to contact centre services for the banking, capital markets, insurance, and asset management domains; and support services. The company was formerly known as i-flex Solutions Limited and changed its name to Oracle Financial Services Software Limited in August 2008. The company was incorporated in 1989 and is based in Mumbai, India. Oracle Financial Services Software Limited is a subsidiary of Oracle Global (Mauritius) Limited.

Top Performing Stocks To Own For 2014: Blue Sky Uranium Corp (BSK.V)

Blue Sky Uranium Corp., a junior mineral exploration company, engages in acquisition, evaluation, and exploration of uranium properties in Canada and Argentina. The company holds interests in a 600,000-hectare land package in the Patagonia region of southern Argentina. Its properties include Santa Barbara and ANIT Uranium project located in the Rio Negro Province of Argentina. Blue Sky Uranium Corp. was incorporated in 2005 and is based in Vancouver, Canada.

Top Safest Stocks To Watch For 2014: Orvana Minerals Com Npv (ORV.TO)

Orvana Minerals Corp., a mining and exploration company, engages in the evaluation, development, and mining of precious and base metal deposits. It primarily explores for gold, copper, and silver ores. The company�s principal property includes the El Vall-Boinas/Carles mine located in the Rio Narcea Gold Belt in northern Spain. It also owns and operates the Don Mario Mine project comprising approximately 70,100 hectares of contiguous concessions situated in eastern Bolivia; and the Copperwood copper project covering approximately 712 hectares in the Upper Peninsula of the state of Michigan, the United States. The company was founded in 1992 and is based in Toronto, Canada.

Top Performing Stocks To Own For 2014: Hudson Technologies Inc.(HDSN)

Hudson Technologies, Inc., through its subsidiary, Hudson Technologies Company, provides refrigerant services and solutions in the refrigeration industry primarily in the United States. Its products and services include refrigerant sales; refrigerant management services consisting primarily of reclamation of refrigerants; RefrigerantSide services comprising system decontamination to remove moisture, oils, and other contaminants. The RefrigerantSide services also include predictive and diagnostic services for industrial and commercial refrigeration applications, which are designed to predict potential catastrophic problems and identify inefficiencies in an operating system. The company?s products and services are primarily used in commercial air conditioning, industrial processing, and refrigeration systems. It sells reclaimed and new refrigerants to customers in air conditioning and refrigeration industry. The company serves commercial, industrial, and government customer s, as well as refrigerant wholesalers, distributors, contractors, and refrigeration equipment manufacturers; and customers in petrochemical, pharmaceutical, industrial power, manufacturing, commercial facility, and property management and maritime industries. Hudson Technologies, Inc. has a strategic alliance with The Linde Group to market its service offering outside the United States. The company was founded in 1991 and is headquartered in Pearl River, New York.

Top Performing Stocks To Own For 2014: Actavis Inc (ACT)

Actavis, Inc., formerly Watson Pharmaceuticals, Inc., incorporated on February 1, 1985, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.

Actavis Pharma Segment

Actavis Pharma Segment is engaged in the development, manufacturing and sale of generic, branded generic and OTC pharmaceutical products. The Company�� portfolio of generic products includes products it has developed internally and products licensed from and distributed for third parties. The Company sells its generic prescription products primarily under the Watson Laboratories, Watson Pharma and Actavis Pharma labels, and its over-the-counter generic products under private label.

Actavis Specialty Brands Segment

The Company markets a number of branded products to physicians, hospitals, and other markets that it serves. The Company classifies these trademarked products as its brand pharmaceutical products. In April 2012, it launched Gelnique 3% (oxybutynin), a clear, odorless topical gel. Gelnique 3% was obtained through an exclusive licensing agreement with Antares. The Company�� promoted products are Rapaflo, Gelnique, Trelstar, Androderm, Generess Fe and Crinone. The Company�� Actavis Specialty Brands segment also receives other revenues consisting of co-promotion revenue and royaltie! s.

Anda Distribution Segment

The Company Anda Distribution business primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables and over-the-counter medicines to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains and physicians��offices. In addition, it sells to members of buying groups, which are independent pharmacies that join together to enhance their buying power. As of December 31, 2012, the Company distributes products from its facilities in Weston, Florida, Groveport, Ohio, and Olive Branch, Mississippi, as well as a small volume of product from Puerto Rico.

The Company competes with Teva Pharmaceutical Industries, Ltd., Mylan Inc., Sandoz, Inc, McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc.,

Advisors' Opinion:

• [By Dan Caplinger]

  What national minimum wages mean for investors
  It's important to realize that minimum-wage laws affect companies only to the extent of their operations in their home countries. For instance, in Australia, mining giants BHP Billiton (NYSE: BHP  ) and Rio Tinto (NYSE: RIO  ) have to follow minimum-wage laws for their Australian operations, but elsewhere around the world, both companies have faced labor disputes over pay levels that in some cases are much lower than what Australian law would require domestically. Moreover, even as Eaton (NYSE: ETN  ) , Actavis (NYSE: ACT  ) , and other companies have moved or are in the process of moving their corporate headquarters to Ireland, you shouldn't expect a huge shift of employees that would require higher pay.

• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Tuesday’s session are Cummins Inc.(CMI), Actavis(ACT) PLC and Huntsman Corp.(HUN)

• [By Sean Williams]

  Geared as a secondary line of treatment, Intercept has geared OCA to snatch up patients who have an inadequate response to, or are unable to take, ursodiol, the only drug currently approved to treat PBC. Ursodiol was originally developed by Actavis (NYSE: ACT  ) (previously Watson Pharmaceuticals) but has since lost its exclusivity, with Lannett (NYSEMKT: LCI  ) gaining FDA approval to market generic versions of the drug in 2008. In the true sense of the word, Intercept has little direct competition as long as ursodiol intolerance exists in some patients.

• [By Rich Smith]

  On Friday, shares of branded pharmaceutical manufacturer Warner Chilcott (NASDAQ: WCRX  ) jumped 20% in response to rumors that the company was in talks to sell itself to larger rival Actavis (NYSE: ACT  ) . Warner also reported steady earnings, where a decline had been expected, and reiterated full-year guidance.